In December 2024, the TRIUMPH-4 Phase 3 trial results were announced, showing that participants taking retatrutide 12 mg achieved an average weight loss of 71.8 pounds or 28.7% of body weight over 68 weeks
A recent case-control study of 1,961 new GLP-1RA patients showed that use of GLP-1RAs significantly reduced the risk of glaucoma, with a hazard ratio of 0.56 [94]
My volume-scaling haircut (30-50% for small peptide doses) is a judgment call, not measured
Obezite Tedavisinde Kullanm BMI deeri 35 kg/m ve zeri olan bireylerde, obeziteye bal bir veya daha fazla salk sorunu varsa (rnein hipertansiyon, uyku apnesi, osteoartrit vb.), Mounjaro uygulanabilir
In clinical research, that effect is often reflected through body weight reduction and waist circumference change over defined protocol windows, and those endpoints are exactly what the phase 2 cagrilintide trial reported
Many patients stay on a therapeutic plan for several months, transitioning to a maintenance phase once goals are achieved